A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Public ClinicalTrials.gov record NCT01116427. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis (MS). Although abatacept is an investigational medication for MS, it is not a new drug. Abatacept has been approved by the FDA to treat rheumatoid arthritis.
Study identification
- NCT ID
- NCT01116427
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2010
- Primary completion
- May 31, 2014
- Completion
- Jan 31, 2015
- Last update posted
- Sep 14, 2016
2010 – 2015
United States locations
- U.S. sites
- 20
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Josephs Hospital and Medical Center - Barrow Neurology | Phonix | Arizona | 85013 | — |
| Jordan Research and Education Institute (REDI): Alta Bates Summit Medical Center | Berkeley | California | 94705 | — |
| University of Southern California - Keck School of Medicine | Los Angeles | California | 90033 | — |
| Newport Beach Clinical Research Associates, Inc. | Newport Beach | California | 92663 | — |
| University of California, Davis | Sacramento | California | 95817 | — |
| University of Miami | Miami | Florida | 33136 | — |
| South Suburban Neurology | Flossmoor | Illinois | 60422 | — |
| Norton Neuroscience Institute - Norton Neurology Services MS Center | Louisville | Kentucky | 40207 | — |
| Louisiana State University | Shreveport | Louisiana | 71130 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| University of Minnesota | Minneapolis | Minnesota | 55414 | — |
| Judith Jaffe Multiple Sclerosis Center: Weill Cornell Medical College | New York | New York | 10065 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| Neurology Specialists, Inc. | Dayton | Ohio | 45417 | — |
| Providence St. Vincent Medical Center | Portland | Oregon | 97225 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| The Neurology Foundation, Inc. | Providence | Rhode Island | 02905 | — |
| Advanced Neurosciences Institute | Franklin | Tennessee | 37064 | — |
| Benaroya Research Institute at Virginia Mason | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Multiple Sclerosis, Relapsing-Remitting trials
Other public records listing Multiple Sclerosis, Relapsing-Remitting. Sorted by last update posted; newest first. Not a recommendation.
- NCT06408259: Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis Recruiting
- NCT06276634: Intermittent Hypoxia in Persons With Multiple Sclerosis Recruiting
- NCT05359653: Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Recruiting
- NCT06413602: The Synergistic Effects of AIH and FES in Persons With MS Active, not recruiting
- NCT06390930: Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS Recruiting
- NCT05201638: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01116427, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2016 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01116427 live on ClinicalTrials.gov.